Pradimicin therapy of disseminated Candida tropicalis infection in the mouse.
BMS 181184 (BMS), an analogue of pradimicin, was administered intravenously to neutropenic mice infected with either a fluconazole-susceptible or a fluconazole-resistant clinical isolate of Candida tropicalis. BMS prolonged survival at doses >3 mg kg -1 day-1, and at higher doses reduced tissue counts in mice. BMS was less potent mg for mg than amphotericin B. Combined BMS and amphotericin B were no more effective than either of the individual drugs.
The University of Texas Health Science Center at San Antonio, USA.
M I
MI
Restrepo
L K
LK
Najvar
A W
AW
Fothergill
J R
JR
Graybill
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects / Q000302:isolation & purification*; D002177:Candidiasis / Q000188:drug therapy*; D004352:Drug Resistance, Microbial; D015725:Fluconazole / Q000494:pharmacology / Q000627:therapeutic use; D007275:Injections, Intravenous; D007668:Kidney / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D013154:Spleen / Q000382:microbiology; D000095643:Pradimicins and Benanomicins
D000666:Amphotericin B; D018943:Anthracyclines; D000903:Antibiotics, Antineoplastic; D000935:Antifungal Agents; D015725:Fluconazole; C066544:pradimicin FA 2; D000095643:Pradimicins and Benanomicins; C077639:3'-hydroxybenanomicin A